Abstracts Archive - Page 122 of 2607 - ACR Meeting Abstracts

Abstract Number: 1679 • ACR Convergence 2025
Does First-Line b- or tsDMARDs Choice Influence Progression to Difficult-to-Treat Rhumatoid arthritis? Insights from our longitudinal RA UCLouvain Brussels cohort
Cécile VAN MULLEM¹, Francesco NATALUCCI¹, Stéphanie DIERCKX¹, Aleksandra AVRAMOVSKA¹, Tatiana SOKOLOVA² and Patrick Durez¹, ¹Cliniques Universitaires Saint-Luc – Université catholique de Louvain (UCLouvain) – Institut de Recherche Expérimentale et Clinique (IREC), Rheumatology, Brussels, Belgium, ²Cliniques Universitaires Saint-Luc – Université catholique de Louvain (UCLouvain) – Institut de Recherche Expérimentale et Clinique (IREC), Rheumatology, Brussels, Brussels Hoofdstedelijk Gewest, Belgium
Background/Purpose: The management of Rheumatoid Arthritis (RA) has markedly advanced, enabling the achievement of disease control and remission. Nevertheless, a proportion of patients remains refractory…
Abstract Number: 1623 • ACR Convergence 2025
The Association of Calprotectin with Vascular Injury and Remodeling in Clinically-Isolated Aortitis
Katarina Kmetova¹, Gavin Poppei², Kavya Sugur³, Julia Ford⁴, Wenying Liang⁴, Emily Chong⁴, Srilakshmi Yalavarthi⁴, NaveenKumar Somanathapura⁴, Nataliya Milman⁵, Peter Merkel⁶, Ora Singer⁷ and Yu (Ray) Zuo⁴, ¹Division of Rheumatology, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor, MI, ²University of Michigan, Ann arbor, ³Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, Ann Arbor, MI, ⁴University of Michigan, Ann Arbor, MI, ⁵the Ottawa Hospital, Ottawa, ON, Canada, ⁶University of Pennsylvania, Philadelphia, PA, ⁷University of Michigan, Huntington Woods, MI
Background/Purpose: Clinically-isolated aortitis (CIA), defined as inflammation of the aortic wall in the absence of extra-aortic arterial involvement, systemic vasculitis, or other associated autoimmune disease,…
Abstract Number: 1562 • ACR Convergence 2025
Vasodilation with Prostanoids Influences Progression of Systemic Sclerosis-Associated Interstitial Lung Disease: a EUSTAR Cohort Study
adela cristina sarbu¹, Liubov Petelytska², lorenzo tofani³, Gianluca Moroncini⁴, Alexandra Balbir-Gurman⁵, elisabetta zanatta⁶, Jörg Henes⁷, paolo airò⁸, Marco Matucci-Cerinic⁹, Ana Maria Gheorghiu¹⁰, antonella marcoccia¹¹, branimir Anić¹², Jelena Colic¹³, Daniel Furst¹⁴, julia Spierings¹⁵, Francesco Del Galdo¹⁶, Britta Maurer¹⁷, Anna-Maria Hoffmann-Vold¹⁸, Oliver Distler¹⁹ and Cosimo Bruni²⁰, ¹Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland. • Department of Rheumatology and Immunology, Bern University Hospital, University of Bern, Bern, Switzerland, bern, Swaziland, ²Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland. • Dept Internal Medicine #³, Bogomolets National Medical University, Kyiv, Ukraine, Kyiv, Ukraine, ³Department of Statistics, Informatics and Applications, University of Florence, Florence, Italy, firenze, Italy, ⁴Department of Internal Medicine, Marche University Hospital, Clinica Medica, Ancona, Italy, Ancona, Italy, ⁵• Rheumatology Institute, Rambam Health Care Campus, Rappaport Faculty of Medicine, Tecchnion, Haifa, Israel, Haifa, Israel, ⁶Padova University Hospital, Rheumatology Unit, Padova, Italy, padova, Italy, ⁷Department of Internal Medicine II, Hematology, Oncology, Clinical Immunology, and Rheumatology, University Hospital Tübingen, Tuebingen, Germany, ⁸Rheumatology and Clinical Immunology Unit, ASST Spedali Civili of Brescia, University of Brescia, Brescia, Italy, brescia, Italy, ⁹University San Raffaele Milano, Milano, Milan, Italy, ¹⁰Spitalul Clinic Dr. Ion Cantacuzino, Bucharest, Romania, ¹¹Centro di Riferimento Interdisciplinare per la Sclerosi Sistemica (CRIIS), Roma, Italy, rome, Italy, ¹²Department of Internal Medicine, Division of Clinical Immunology and Rheumatology, University of Zagreb, School of Medicine, University Hospital Center Zagreb, Croatia, zagreb, Croatia, ¹³Institute of Rheumatology Belgrade, Belgrade, Serbia, Belgrade, Serbia, ¹⁴Southern California Scleroderma and Rheumatology Center, Los Angeles, CA, ¹⁵Department of Rheumatology & Clinical Immunology, University Medical Center, Ultrecht, The Netherlands, Utrecht, Netherlands, ¹⁶University of Leeds, Leeds, United Kingdom, ¹⁷Department of Rheumatology & Immunology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland, ¹⁸Oslo University Hospital, Oslo, Norway, ¹⁹Department of Rheumatology, University Hospital Zurich, University of Zurich, Switzerland, Zurich, Switzerland, ²⁰University of Zurich, Zurich, Switzerland
Background/Purpose: Although most vasoactive vasodilating drugs (VVDs) exert anti-fibrotic effects in pre-clinical studies, randomized controlled trials assessing their efficacy in systemic sclerosis-associated interstitial lung disease…
Abstract Number: 1650 • ACR Convergence 2025
Malondialdehyde-Acetaldehyde and Citrulline Modified Proteins are Overexpressed in Cardiac Tissues in Rheumatoid Arthritis-Associated Heart Failure and Mediate Endothelial Cell Dysfunction
Hannah Johnson¹, Wenxian Zhou², Michael Duryee¹, Engle Sharp¹, Kimberley Sinanan¹, Carlos Hunter¹, Tate Johnson¹, Mabruka Alfaidi¹, Daniel Anderson³, Geoffrey Thiele¹ and Ted Mikuls¹, ¹University of Nebraska Medical Center, Omaha, NE, ²University of Nebraska Medical Center, Bellevue, NE, ^30587964, Durham, NC
Background/Purpose: Previous reports show that malondialdehyde-acetaldehyde (MAA) adducts are overexpressed in RA, especially in joint/lung tissues, and that they colocalize with citrulline (CIT). This is…
Abstract Number: 1660 • ACR Convergence 2025
Digital Psychological Support for Inflammatory Rheumatic Diseases: A Randomized Clinical Trial
Johannes Knitza¹, Julia Kraus², Martin Krusche³, Isabell Haase³, Philipp Klemm⁴, Axel Hueber⁵, Pfeil Alexander⁶, Ulrich Drott⁷, Sebastian Kuhn⁸ and Jan Philipp Klein⁹, ¹Institute for Digital Medicine, University Hospital Gießen-Marburg, Philipps University, Marburg, Germany, ²Vila Health, Berlin, Germany, ³Division of Rheumatology and Systemic Inflammatory Diseases, III. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, ⁴Department of Rheumatology and Clinical Immunology Center, JLU Giessen, Campus Kerckhoff, Bad Nauheim, Germany, Bad Nauheim, Germany, ⁵Klinikum Nuernberg, Nuernberg, Germany, ⁶Department of Internal Medicine III, Jena University Hospital - Friedrich Schiller University Jena, Jena, Germany, ⁷Deutsches Endokrinologisches Versorgungszentrum, Frankfurt, Germany, ⁸Institute for Digital Medicine, University Hospital of Giessen and Marburg, Philipps University Marburg, Marburg, Germany, ⁹Department of Psychiatry, Psychosomatics and Psychotherapy, University of Lübeck, Lübeck, Germany
Background/Purpose: Patients with inflammatory rheumatic diseases (IRDs) frequently experience psychological distress, however access to psychological support remains limited. The aim of this trial (DRKS identifier:…
Abstract Number: 1628 • ACR Convergence 2025
Characterization of non-GCA, non-Takayasu Aortitis in a Single Health System Cohort
Nuzhat Batool¹, Zuha Anwar¹, Sharika Hasan², Miltiadis Tembelis², Jason Hoffmann¹, Nihan Gencerliler², justeena Joseph³, Steven Carsons⁴ and Elise Belilos¹, ¹NYU Grossman LI School of Medicine, Queens, NY, ²NYU Grossman LI School of Medicine, Queens, ³Long Island Community Hospital, Long Island, NY, ⁴NYU Long Island School of Medicine, Mineola, NY
Background/Purpose: Advances in imaging modalities has led to increased diagnosis of aortitis. While aortitis occurring in the setting of giant cell arteritis (GCA) and Takayasu…
Abstract Number: 1688 • ACR Convergence 2025
Impact of Stress, Anxiety, and Depression on Fatigue as moderated by Resilience and Exposure to Trauma in Rheumatology Patients
Akhila Veeravalli¹, Sankeerthana gajjala² and Sarath Chandra Mouli Veeravalli³, ¹Department of Rheumatology, KIMS Hospitals, Secuderabad, India, Hyderabad, Telangana, India, ²KIMS Hospitals, Secunderabad, India, Hyderabad, Telangana, India, ³Dept. of Rheumatology and Clinical Immunology, KIMS Hospitals, Secunderabad, India, Hyderabad, Telangana, India
Background/Purpose: This study aimed to examine the impact of psychological distress—specifically stress, anxiety, and depression—on fatigue in rheumatology patients, and explored how this relationship is…
Abstract Number: 1632 • ACR Convergence 2025
PET/CT-Based Distribution of Arterial Involvement and Its Association With Clinical Outcomes in Takayasu Arteritis
Tokio Katakura¹, Tsuyoshi Shirai², Kentaro Mori¹, Mikihiro Takahashi¹, Yuito Tanno³, Soshi Okazaki³, So Itoi³, Yosuke Hoshi³, Tomoaki Machiyama³, Yusho Ishii³, Hiroko Sato³ and Hiroshi Fujii³, ¹Department of Rheumatology, Tohoku University Hospital, Sendai, Japan, ²Department of Rheumatology, Tohoku University Hospital, Sendai, Miyagi, Japan, ³Department of Rheumatology, Tohoku University Hospital, Sendai

Background/Purpose: PET/CT enables assessment of active vascular inflammation in Takayasu arteritis (TAK), which is often difficult to evaluate with conventional imaging. Although the distribution of…
Abstract Number: 1669 • ACR Convergence 2025
Development and Validation of Minimal Disease Activity and Disease Flare for Children with Chronic Nonbacterial Osteomyelitis Using a Consensus and Data-Driven Approach
Farzana Nuruzzaman¹, Natalie Rossenwasser², Xing Wang³, Ava Klein³, Ian Muse⁴, Erin Balay-Dustrude⁵, Megan Nguyen⁶, Emily Deng³, Jonathan Akikusa⁷, Matthew Basiaga⁸, Lindsey Bergstrom⁹, Fatma Dedeoglu¹⁰, Bin Huang¹¹, Jenna King¹², Sivia Lapidus¹³, Tzielan Lee¹⁴, Aleksander Lenert¹⁵, Cassandra Levesque¹⁶, Lillian Lim¹⁷, Kimberly Martin¹⁸, Elizabeth Murray¹⁹, Melissa Oliver²⁰, Karen Onel²¹, Seza Özen²², Lauren Potts²³, Sara M. Stern²⁴, Robin Villaverda²⁵, Eveline Wu²⁶, Ronald laxer²⁷, Polly Ferguson²⁸, Daniel Lovell²⁹ and Yongdong (Dan) Zhao³⁰, ¹Stony Brook Children's Hospital, Stony Brook, NY, ²Seattle Children's Hospital, Seattle, WA, ³Seattle Children's Hospital, Seattle, ⁴University of Washington, Department of Pediatrics, Seattle Children's Hospital, Seattle, ⁵University of Washington, Seattle, WA, ⁶Seattle Children’s Research Institute, Seattle, ⁷The Royal Children's Hospital, Parkville, Victoria, Australia, ⁸Mayo Clinic, Rochester, MN, ⁹Patient/parent research partner, Harpswell, ME, ¹⁰Boston Children's Hospital, Boston, MA, ¹¹Cincinnati Children's Hospital, Cinciannati, OH, ¹²Patient/parent Research Partner, Planation, FL, ¹³Joseph M. Sanzari Children's Hospital, Center for Discovery and Innovation, Hackensack Meridian School of Medicine, Montclair, NJ, ¹⁴Stanford University School of Medicine, Palo Alto, CA, ¹⁵Iowa Carver College of Medicine, Iowa City, IA, ¹⁶Patient/parent research partners, DC district, DC, ¹⁷University of Alberta, Edmonton, AB, Canada, ¹⁸Patient/parent research partners, Houston, TX, ¹⁹Patient/parent research partners, Lynnwood, WA, ²⁰Indiana University, Indianapolis, IN, ²¹HSS, New York, NY, ²²Hacettepe University Medical Faculty, Ankara, Turkey, ²³Patient/parent research partners, Santa Cruiz, CA, ²⁴University of Utah, Salt Lake City, UT, ²⁵Patient/parent research partners, Thorton, CO, ²⁶UNC Chapel Hill, Chapel Hill, NC, ²⁷The Hospital for Sick Children, Toronto, ON, Canada, ²⁸University of Iowa Carver College of Medicine, Iowa City, IA, ²⁹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³⁰Seattle Children’s Research Institute, Redmond, WA
Background/Purpose: Chronic nonbacterial osteomyelitis (CNO) is an inflammatory bone disease that can result in bone destruction/deformity, persistent bone pain and pathological fractures. Due to the…
Abstract Number: 1529 • ACR Convergence 2025
Updated Phase 1 Trial Data Assessing the Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of BMS-986353 (CC-97540), a CD19-directed Chimeric Antigen Receptor T Cell Therapy Using a Next-Generation Process for Severe, Refractory SLE
Georg Schett¹, David Simon², Margrit Wiesendanger³, Anca Askanase⁴, Vikas Majithia⁵, Neil Kramer⁶, Jacques Morel⁷, Philip J. Mease⁸, Ellen De Langhe⁹, Amit Saxena¹⁰, dominique Farge¹¹, Alain Lescoat¹², Alisha Desai¹³, Griff McTume¹⁴, Whitney Handy¹⁴, Sharmila Das¹³, Jerill Thorpe¹⁴, Alexis Melton¹⁴, Ashley Koegel¹⁴ and Emily Littlejohn¹⁵, ¹Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany, ²Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany; Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, Berlin, Germany, ³Icahn School of Medicine at Mount Sinai, New York, NY, ⁴Columbia University Medical Center, New York, NY, ⁵Mayo Clinic Hospital, Jacksonville, FL, ⁶Overlook Medical Center; Atlantic Medical Group, Atlantic Health System, Summit, NJ, ⁷CHU and University of Montpellier, Montpellier, France, ⁸Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ⁹University Hospitals Leuven, Leuven, Belgium, ¹⁰Division of Rheumatology, Department of Medicine, NYU Grossman School of Medicine, New York, NY, ¹¹Hôpital Saint-Louis, Paris, France, ¹²CHU Rennes University Hospital, Rennes, France, ¹³Bristol Myers Squibb, Princeton, NJ, ¹⁴Bristol Myers Squibb, Princeton, ¹⁵Cleveland Clinic, Cleveland, OH
Background/Purpose: BMS-986353 (CC-97540; CD19 NEX-T) is a CD19-directed chimeric antigen receptor (CAR) T cell therapy that expresses the same CAR as lisocabtagene maraleucel (liso-cel); it…
Abstract Number: 1689 • ACR Convergence 2025
Addressing Perceived Discrimination in Lupus Care: Enhancing Patient Empowerment and Health Equity Through Education and Support
Kimberly Cabrera¹, Priscilla Calvache², Lillian Mendez³, Giselle Morales⁴ and Jillian Rose-Smith², ¹Hospital for Special Surgery, New York, ²Hospital for Special Surgery, New York, NY, ³Patient Advocate, Carteret, NJ, ⁴Hospital for Special Surgery, Glendale, NY
Background/Purpose: SLE is a life-threatening autoimmune disease that disproportionately affects African American (AA), Hispanic/Latino, & Asian populations. These communities experience serious health disparities, including more…
Abstract Number: 1641 • ACR Convergence 2025
Association of Area Socioeconomic Deprivation with Community Mobility in a Diverse Cohort of Individuals with SLE
Laura Plantinga¹, C. Barrett Bowling², S. Sam Lim³, Patti Katz⁴ and Jinoos Yazdany⁵, ¹University of California, San Francisco, San Francisco, CA, ²Duke University, Durham, NC, ³Emory University School of Medicine, Atlanta, GA, ⁴UCSF, San Rafael, CA, ⁵UCSF, San Francisco, CA
Background/Purpose: Community mobility (the extent to which individuals move independently throughout their community) is suboptimal among those with SLE, particularly for those who are Black,…
Abstract Number: 1656 • ACR Convergence 2025
Risk of Serious Infection associated with non-TNF biologic initiation after Anti-TNF Use in Older Adults with Rheumatoid Arthritis
Jiha Lee¹, Sofia Pedro² and Kaleb Michaud³, ¹University of Michigan, Ann Arbor, ²Forward, The National Databank for Rheumatic Diseases, Wichita, KS, ³University of Nebraska Medical Center, Omaha, NE
Background/Purpose: In older adults with rheumatoid arthritis (RA), anti-TNF therapies are typically used as first-line biologic treatment. However, many patients require a switch to non-TNF…
Abstract Number: 1556 • ACR Convergence 2025
Latent Profiles of Parenchymal Abnormalities and Vascular Features Measured by Quantitative CT Identifies a Subgroup of Systemic Sclerosis Patients With a Greater Lung Function Decline Over Time
Alicia Hinze¹, Nishanth Katurkuri², Robert Vassallo², Ami Shah³, Ryan Lennon², Brian Bartholmai² and Cynthia Crowson⁴, ¹Mayo Clinic - Rochester, MN, Rochester, MN, ²Mayo Clinic, Rochester, MN, ³Johns Hopkins Rheumatology, Baltimore, MD, ⁴Mayo Clinic, Stewartvillle, MN
Background/Purpose: The clinical course of interstitial lung disease (ILD) in systemic sclerosis (SSc) is highly variable--some patients experience progressive loss of lung function while others…
Abstract Number: 1675 • ACR Convergence 2025
Neuroimmune modulation in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitors (TNFi)
Guillermo Valenzuela¹, Jane Box², Angela Crowley³, Joshua June⁴, Pendleton Wickersham⁵, Jeff Peterson⁶, Michael Thakor⁷, Susan Kim⁸, Tina Shah⁹, David Chernoff¹⁰ and John Tesser¹¹, ¹Integral Rheumatology & Immunology Specialists, Plantation, FL, ²DJL Clinical Research, PLLC, Charlotte, NC, ³Illinois Bone and Joint Institute - Hinsdale Orthopaedics, Hinsdale, IL, ⁴Great Lakes Center of Rheumatology, Lansing, MI, ⁵Arthritis Associates PA, San Antonio, TX, ⁶Western Washington Arthritis Clinic, Seattle, WA, ⁷arthritis and rheumatology, Fort Collins, CO, ⁸Lehigh Valley Hospital Network, Allentown, PA, ⁹Kansas City Physician Partners, Kansas City, MO, ¹⁰SetPoint Medical, Sausalito, CA, ¹¹Arizona Arthritis & Rheumatology Associates, Phoenix, AZ
Background/Purpose: A substantial number of patients with rheumatoid arthritis (RA) experience treatment failure, incomplete response, or intolerance to TNFis (TNFi-IR). Neuroimmune modulation using an implantable…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].